Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

NCT00137865 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decided to terminate the study early so they could begin a second dose-escalation study of EGEN-001 in combination with standard chemotherapy.

Conditions

Interventions

Sponsor

EGEN, Inc.